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There has been rapid growth in research regarding the use of live bacterial cells for therapeutic purposes. The recognition that
these cells can be genetically engineered to synthesize products that have therapeutic potential has generated considerable interest
and excitement among clinicians and health professionals. It is expected that a wide range of disease modifying substrates such as
enzymes, hormones, antibodies, vaccines, and other genetic prod u c t sw i l lb eu s e ds u c c e s s f u l l ya n dw i l li m p a c tu p o nh e a l t hc a r e
substantially. However, a major limitation in the use of these bacterial cells is the complexity of delivering them to the correct target
tissues. Oral delivery of live cells, lyophilized cells, and immobilized cells has been attempted but with limited success. Primarily,
this is because bacterial cells are incapable of surviving passage through the gastrointestinal tract. In many occasions, when given
orally, these cells have been found to provoke immunogenic responses that are undesirable. Recent studies show that these problems
can be overcome by delivering live bacterial cells, such as genetically engineered cells, using artiﬁcial cell microcapsules. This review
summarizes recent advances in the therapeutic use of live bacterial cells for therapy, discusses the principles of using artiﬁcial cells
for the oral delivery of bacterial cells, outlines methods for preparing suitable artiﬁcial cells for this purpose, addresses potentials
and limitations for their application in therapy, and provides insight for the future direction of this emergent and highly prospective
technology.
ORAL DELIVERY OF LIVE BACTERIAL CELLS FOR
THERAPY: POTENTIALS AND LIMITATIONS
Intestinal ﬂora are key to human health, as they play
an important role in metabolic processes [1, 2]. With ad-
vances in genetic engineering, it is now possible to en-
hance this metabolic capacity. It is also possible to engi-
neernonpathogenicnormalcellsfordesiredmetabolicac-
tivity and to produce therapeutic agents. Thus, inherited
or engineered availability of special properties in these
cells make them excellent candidates for therapeutic use.
Indeed, the concept of ingesting live microorganisms for
therapy (probiotics) can be traced back to the beginning
of the 20th century [3].
Since then, several promising studies have substan-
tiated this concept. For example, oral feeding on Lacto-
bacillus bacteria has been used for prevention and treat-
ment of diarrhea in children [4, 5, 6]. Similarly, feed-
ing on Lactobacillus casei strain Shirota (LcS) has been
shown to enhance innate immunity [7]. Bacteria such as
Biﬁdobacteria have been successfully used to treat intesti-
nal disorders and to prevent rotaviral diarrhea in chil-
dren [8]. In premature infants, feeding on lyophilized
strains of Bb r e v eor B longum can restore the imbal-
ance in the gut microﬂora [9, 10]. These latter strains can
also suppress azomethane-induced colon carcinogenesis
in rats [9]. Cultures of B longum reduced carcinogene-
sis by a food mutagen, 2-amino-3-methylimidazo [4,5-
f]quinoline [9]. Certain strains of Lactobacilli have also
been shown to signiﬁcantly suppress intestinal tumors in-
ducedbychemicalmutagens[9,11].Somehumanfeeding
studies with Lactobacilli suggest a possible eﬀect in low-
ering cholesterol [9, 12, 13]. Recently, in a randomized,
double-blind study, 27 healthy newborn infants were col-
onizedwiththenonpathogenicEcoli1917 duringtheﬁrst
5 days of life by daily oral inoculation (1.0mL suspension
containing 108 live cells). The colonization with true and
potential bacterial pathogens was signiﬁcantly reduced in
infants receiving Ec o l i1917 [14]. Oral feeding on freeze-
dried live Lactobacillus (LB) acidophilus cells in subjects
with advanced chronic kidney failure has been shown to
lower elevated levels of uremic toxins [15].
In another study, a carcinogen, nitrosodimethylamine
(NDMA),andthetoxindimethylamine(DMA)werelow-
ered signiﬁcantly by oral feeding on LB cells with no side
eﬀects of the therapy. Other studies indicate that renal
failure stones can be treated using high concentrations of
freeze-dried lactic acid bacteria [16], LB cells can change
small bowel pathobiology reducing in vivo generation of
toxins and carcinogens with no adverse side eﬀects [15],
plasma uremic toxins canbe markedly lowered in patients
after oral administration of LB cells [16], and bactericides2005:1 (2005) Delivery of Live Bacteria in Artiﬁcial Cells for Therapy 45
and Ec o l icells can be used to treat gastrointestinal (GI)
tract disorders [17]. In addition, there is also evidence
to suggest that ingesting a strain of Biﬁdobacterium lac-
tis can enhance general immunity [18], and that ingesting
certain strains of LB cells can increase secretary IgA lev-
els and rotavirus-speciﬁc antibodies [19, 20]. Recently, it
was demonstrated that Lactococcus lactis bacteria can be
genetically engineered to produce cytokine interleukin-10
(IL-10) and it can be used for inﬂammatory bowel disease
(IBD) therapy by oral delivery [21]. Thus, there is consid-
erableevidencesupportingtheimportanceoforalfeeding
on live normal or genetically engineered bacterial cells for
diverse therapeutic applications highlighting the underly-
ing potential of this approach to therapy. Table 1 summa-
rizes the potential of the use of bacterial cells to therapy.
While existing live bacterial cell therapies show great
therapeutic potential, they have several limitations. For
instance, when given orally bacterial cells are exposed
to diﬃcult GI conditions and experience low survival
[22, 23, 24] requiring that a large dosage be given. How-
ever,largequantitiesoflivebacterialcells,deliveredorally,
can stimulate host immune response [25, 26, 27, 28, 29].
In fact, a normal daily intake of 250mL of yogurt would
only correspond to 500 milligrams of cell dry weight
(CDW)ofbacteria,andofthosebacteriaingestedonly1%
wouldsurvivegastrictransitlimitingtheoveralltherapeu-
tic eﬀect [30]. Furthermore, when given orally, live bacte-
rial cells can be retained in the intestine [26, 27, 31, 32]
and repeated large doses could result in their replacing
the normal intestinal ﬂora [33]. In addition, risk of sys-
temicinfections,deleteriousmetabolicactivities,adjuvant
sideeﬀects,immunomodulation,andriskofgenetransfer
limit their widespread use [26, 32, 34, 35, 36]. These lim-
itations have raised concerns about the safety of the ap-
proach and prevented receiving approval from regulatory
agenciesandhenceprecluded theadoption ofthis formof
therapy in regular clinical practice [26, 32, 34, 35, 36, 37].
POTENTIAL OF ARTIFICIAL CELLS FOR ORAL
DELIVERY OF LIVE BACTERIAL CELLS FOR THERAPY
Principleofartiﬁcialcellsfororaldelivery
ofbacterialcellsfortherapy
Artiﬁcial cell microencapsulation is a technique used
to encapsulate biologically active materials in specialized
ultrathin semipermeable polymer membranes [58, 59].
The polymer membrane can protect encapsulated mate-
rials from harsh external environments while at the same
time allowing for the metabolism of selected solutes ca-
pable of passing into and out of the microcapsule. In this
manner, the enclosed material (in this case live bacteria)
can be retained inside and separated from the external en-
vironment, making microencapsulation particularly use-
ful for biomedical and clinical applications [60, 61, 62].
Studies show that artiﬁcial cell microcapsules can be used
for oral administration of live genetically engineered cells
that can be useful for therapeutic functions [63, 64]. Al-
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Figure 1. The principle of orally administered artiﬁcial cells
containing bacterial cells for therapy. The semipermeable mem-
brane excludes antibodies, tryptic enzymes, and other external
materials but allows smaller molecules (amino acids, bile acids,
ammonia, gasses, etc) to enter and be acted on by the enclosed
microorganisms. Also, small molecules (including some pep-
tides) produced by the enclosed bacterial cells can be designed
to diﬀuse out into the body for therapy.
though the live cells remain immobilized inside the mi-
crocapsules, microencapsulation does not appear to hin-
der their growth kinetics [65]. The microcapsules remain
intact during their passage through the intestinal tract
and are excreted intact in the stool in about 24 hours.
The cells are retained inside, and excreted with, the intact
microcapsules addressing many of the major safety con-
cerns associated with the use of live bacterial cells for var-
ious clinical applications. The membranes of the micro-
capsules are permeable to smaller molecules, and thus the
cells inside the microcapsules metabolize small molecules
found within the gut during passage through the intestine
[58,63,64,65,66,67].Figure 1summarizesthebasiccon-
cept of artiﬁcial cells for oral delivery of bacterial cells for
therapy.
The GI tract provides a blood/environment interface
thatweuseoftenfornutrition,excretion,maintainingwa-
ter and electrolyte balance, and occasionally for various
therapies including the delivery of drugs. Interaction with
this system through input of nutrients, water, and drugs46 S. Prakash and M. L. Jones 2005:1 (2005)
Table 1. Potential therapies based on the oral delivery of free live bacterial cells.
Disease/therapy Culture Mode of action References
Diarrhea
L rhamnosus
Lc a s e i
Lr e u t e r i
LG GBl a c t i s
B biﬁdum
B Bb12
Reduction of antibiotic-associated diarrhea in children and adults,
treatment and prevention of rotavirus and acute diarrhea in children and
adults, prevention of traveler’s diarrhea. Certain strains of lactic acid
bacteria promote serum and intestinal immune responses to rotavirus and
thus may be important in establishing immunity against rotavirus
infections.
[4, 5, 6, 8,
17, 19, 20,
38, 39, 40,
41, 42, 43,
44, 45, 46]
US
Patent
5 443 826
Colorectal
cancer
Lactobacillus
Bb r e v e
Bl o n g u m
Mechanisms may include enhancing the host’s immune response;
binding and degrading potential carcinogens; alterations in the intestinal
microﬂora incriminated in producing recognized carcinogens (eg, bile
acid-degrading bacteria); producing anticarcinogenic or antimutagenic
compounds in the colon; alteration of the metabolic activities of the
resident microﬂora; alteration of physicochemical conditions; eﬀects on
general physiology.
[9, 10,
11, 47]
Inﬂammatory
bowel disease
Ll a c t i s
LG G
Could provide an adjunct nutritional therapy for Crohn’s disease, as the
bacteria increase gut IgA immune response promoting the gut
immunological barrier.
[17, 48]
US
Patent
5 443 826
Ulceration L acidophilus Downregulation of Hp y l o r iinfection by inhibition of intestinal cell
adhesion and invasion.
[49]
Steatorrhea of
lipids
(malabsorption
of lipids)
B plantarii
Bacteria express lipolytic activity with substantial enzyme stability in
human gastric juice leading to the increased absorption of lipids in the
small intestine.
[50, 51]
Enhanced
immunity
L acidophilus
Lc a s e i(LcS)
LG G
Bl a c t i s
B biﬁdum
By one mechanism, innate immunity is enhanced by stimulating the
activity of splenic NK cells. While antigen-feeding alone was shown to
prime for an immune response, cofeeding on antigen and probiotic
bacteria suppressed both antibody and cellular immune responses and
may have the potential to attenuate autoimmune diseases (eg,
encephalomyelitis) by jointly dosing with myelin basic protein and
probiotic bacteria.
[7, 52,
53, 54]
Lower
cholesterol
L acidophilus
L bulgaricus
Lr e u t e r i
(1) Bacteria may bind or incorporate cholesterol directly into the cell
membrane.
(2) Bile salt hydrolase (BSH) enzyme deconjugates intraluminal bile acids
making them less likely to be reabsorbed into the enterohepatic
circulation (ECH), causing de novo synthesis of bile acids from blood
serum cholesterol (Figure 2).
[12, 13, 55]
Chronic kidney
failure
L acidophilus
Lactic acid
bacteria
S m a l lb o w e lb a c t e r i a lo v e r g r o w t hi sw e l lk n o w nt oo c c u ri ne n d - s t a g e
kidney failure and is responsible for producing uremic toxins and
contributing to decreased nutritional well-being. Certain bacteria are
shown to reduce blood levels of uremic toxins produced in the intestine
as bacterial putrefactive metabolites, especially that of indican,
dimethylamine, and nitrosodimethylamine (a carcinogen) by inhibiting
bacterial production by means of correcting the intestinal microﬂora.
[15, 56]
Kidney stones
L acidophilus,
L plantarum
Lb r e v i s
S thermophilus
Bi n f a n t i s
Of a e c a l i s
Urinary excretion of oxalate, a major risk factor for renal stone formation
and growth in patients with idiopathic calcium-oxalate urolithiasis, can
be greatly reduced with treatment using a high concentration of freeze-
dried lactic acid bacteria. Oxalate-degrading enzymes produced by these
microorganisms or by Oxalobacter-type bacteria breaks down the
unwanted oxalate and can be used to prevent the subsequent evolution of
kidney stones.
[16, 57]2005:1 (2005) Delivery of Live Bacteria in Artiﬁcial Cells for Therapy 47
(a) (b)
(c) (d)
Figure 2. Artiﬁcial cells for bacterial cell therapy in kidney failure, elevated blood cholesterol, and other diseases. (a) Empty APA
artiﬁcial cells. (b) APA membrane artiﬁcial cells with visible engineered Ec o l iDH5 cells; with permission from Chang and Prakash
[72]. (c) Empty APA artiﬁcial cells. (d) APA membrane artiﬁcial cells with thousands of engineered L plantarum 80 (pCBH1) cells;
with permission from Jones et al [101].
is further complicated by the fact that the GI tract main-
tains severalinternal cyclesusedtopreserve the balanceof
various molecules like bile acids, amino acids, and other
recyclable molecules. This enterorecirculation thus pro-
vides an opportunity for the therapeutic action of encap-
sulatedbacterialcells.Bythismotivation,interactionwith
this vast interface poses great interest to nutritional health
scientists, advocates of probiotics, designers of oral drugs,
and more recently those interested in oral therapy with
live bacterial cells.
Artiﬁcial cells are enormously versatile in that they
may contain gasses, drugs, enzymes, antibodies, cell ex-
tracts, polymers, proteins, and evenwhole cells. For many
applications a single trapped enzyme or delivered drug
may provide a curative eﬀect; however, in many other
cases the breakdown of an unwanted metabolite, or the
production of a protein, may be better carried out by a
microorganism. That is to say, the complex metabolism
of various microorganisms can be encapsulated and used,
in eﬀect, as miniature bioreactors for therapy. Also, the
hardy growth characteristics and short replication times
of various bacterial strains make them perfect for mass
production and as eﬀective agents for orally delivered ar-
tiﬁcial cell therapy. Furthermore, as mentioned earlier
in the last two decades, there has been an explosive in-
crease in molecular biology research leading to the gen-
eration of many genetically engineered microorganisms
with special properties. Microorganisms can be easily en-
gineered to overproduce enzymes and peptides and to
metabolize large amounts of unwanted metabolites and
others. For these reasons, artiﬁcial cells containing bac-
terial cells are very good candidates for oral artiﬁcial cell
therapy Figure 2. This concept has immediate application
for microencapsulation-based oral therapy in renal fail-
ure and liver failure [63], physiologically responsive gene
therapy [58, 68], and somatic gene therapy [69].
Methodsforpreparingartiﬁcialcells
The versatility of various formulations of artiﬁcial
cells has been well documented; however, choosing a
membrane is not a “one-size-ﬁts-all” decision—artiﬁcial
cell membranes should be selected or designed for each
speciﬁc therapeutic device, as one may engineer several
diﬀerent membranes for artiﬁcial cell preparations with
required membrane properties for a desired application.
The use of diﬀerent membranes allows for variations in
permeability, mass transfer, mechanical stability, buﬀer-
ing capability, biocompatibility, and other characteristics.
A balance, however, has to be maintained among the
physical properties of capsule membranes so as to sup-
port the entrapped cells’ survival. The mass transport
properties of a membrane are critical since the inﬂux
rate of molecules, essential for cell survival, and the out-
ﬂow rate of metabolic waste ultimately determine the vi-
ability of entrapped cells. Ordinarily the desired capsule48 S. Prakash and M. L. Jones 2005:1 (2005)
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Membrane
(Molecular weight cutoﬀ)
MWCO for hollow
ﬁber membrane
(> 200kd)
MWCO for APA
membrane
(60–70kd)
MWCO for
cellulose nitrate
or polyamide
(30kd)
MWCO for
lipid-complexed
polymer
(100–200d)
MWCO for
lipid vesicles
(lipophilic)
Leukocytes
IgM (950kd)
Urease (482.7kd)
C19 (410kd)
Fibrinogen (339kd)
Phenylalanine NH3 lyase (320kd)
Catalase (247kd)
C4 (210kd)
C5 (195kd)
IgE (190kd)
Human leucocytes antigen (180–210kd)
C3 (185kd)
IgA (170–720kd)
C2 (170kd)
C8 (163kd)
IgD (160kd)
IgG (150kd)
Tyrosinase (128kd)
C6 (110kd)
C7 (100kd)
Transferrin (81kd)
C9 (79kd)
Albumin (66.248kd)
Hemoglobin (64kd)
FactoreX(55kd)
TNF (51kd)
Superoxide dismutase (31.187kd)
IL-beta (17kd)
NGF (13kd)
C3a (9000d)
Insulin (5733d)
C5a (4000d)
Beta-endorphin (3438d)
Glucose (180d)
Tyrosine (163d)
Phenylalanine (147d)
Glutamine (128d)
Aspargine (114d)
Creatinine (113d)
Urea (60 d)
Carbon dioxide (44d)
Ammonia (17d)
Oxygen (16d)
Figure 3. Molecular cutoﬀ of diﬀerent types of microcapsule membranes [72]. The molecular weights of various cells, enzymes,
antibodies,complementcomponents,proteins,peptides,andmetabolitesarelistedontheright.Abbreviations:C2–9andC19,various
components of the complement cascade; Ig, immunoglobulin; IL-1, interleukin 1; NGF, nerve growth factor.
permeability is determined by the molecular weight cut-
oﬀ (MWCO) and is application-dependent. The MWCO
is the maximum molecular weight of a molecule that is
allowed passage through the pores of the capsule mem-
brane [70]. For transplantation, the MWCO must be high
enough to allow passage of nutrients but low enough
to reject antibodies and other immune molecules. The
MWCO of orally delivered microcapsules must allow for
the passage of unwanted metabolites from the plasma
into the microcapsule and then must either facilitate the
subsequent removal of the altered molecule or provide
for its storage [70] .T h em o s tc o m m o nt y p eo fm e m -
brane used for cell therapy is the single alginate-based
polymer membrane; however, several other substances
are being used such as various proteins, polyhemoglobin,
and lipids [70, 71] .Y e ta n o t h e ra p p r o a c hf o rm e m b r a n e
composition is to use a biodegradable synthetic poly-
mer such as polylactide, polyglycolic acid, and polyanhy-
dride. Figure 3 summarizes some commonly used artiﬁ-
cial cell membranes and their molecular properties. The2005:1 (2005) Delivery of Live Bacteria in Artiﬁcial Cells for Therapy 49
variability of artiﬁcial cell membranes allows for many
possibilities in live cell therapy and other procedures and
raises expectations for their widespread use in the future.
Theclassicmethodofpreparingartiﬁcialcellmicrocapsules
containinglivebacterialcells
There are various methods available for preparing
artiﬁcial cells containing live bacterial cells for ther-
apy. For example, for preparation of the classic alginate-
polylysine-alginate (APA) membrane, the live bacterial
cells are suspended in a matrix of the natural polymer al-
ginate (1.5%). The viscous polymer-bacterial suspension
ispassedthrougha23-gaugeneedleusingasyringepump.
Sterile compressed air, passed through a 16-gauge coax-
ial needle, is then used to shear the droplets coming out
of the tip of the 23-gauge needle. The droplets are al-
lowed to gel for 15 minutes in a gently stirred ice-cold
solution of solidifying chemicals, such as CaCl2 (1.4%).
A f t e rg e l a t i o ni nt h eC a C l 2, the beads are then washed
with HEPES (0.05% in HEPES, pH 7.20), coated with
polylysine (0.1% for 10minutes) and washed again in
HEPES (0.05% in HEPES, pH 7.20). The resultant cap-
sules are then coated by reaction with alginate (0.1% for
10minutes) and washed with appropriate chemicals to
dissolve their inner core content. For this step a 3.00% cit-
rate bath (3.00% in 1 : 1 HEPES-buﬀer saline, pH 7.20) is
often used. The microcapsules formed can then be stored
at 4 ◦C in minimal solution (10% cell nutrient to 90% wa-
ter).
Mechanicalstability
If more sturdy microcapsules are required and the
above method fails to produce the desired quality of mi-
crocapsules, a second more complex method can be em-
ployed. It is a 2-step method developed by Wong and
Chang [73, 74]. Brieﬂy, much smaller alginate beads
containing live cells are produced at a much higher shear
force than above. One millilitre of these small alginate gel
beads are then added to 1mL solution of sodium alginate
(1.2%–1.6%). The rest of the method is the same as above
starting with droplet formation using a 23G needle. This
extra step will prevent cell leakage and limit the exposure
ofsurfaceantigensfoundonthemembranesoftheencap-
sulated microorganisms.
Large-scaleproductionofartiﬁcialcellmicrocapsules
Iflarge-scalepreparationofsterilemicrocapsulescon-
taining bacterial cells is required, automated encapsula-
torssuchastheInotechEncapsulatorproducedbyBiosys-
tems International Inc (Rockville, Md, USA) can be used.
This type of encapsulator is not based on the shear drop
method,butisbasedontheprinciplethatalaminarliquid
jetisbrokenintoequallysizeddropletsbyasuperimposed
vibration. Furthermore, an electrostatic charge may be
applied to each microcapsule so that a funnel-like spray
of droplets is produced and a more homogeneous set of
microcapsules result. This type of microencapsulator can
manufacturelargenumbersofsuperior-qualitymicrocap-
sules and can facilitate the procedures described in the
methods outlined above.
Membranesusedforartiﬁcialcellsfor
oraldeliveryofbacterialcells
The design of a membrane, intended for use in oral
live bacterial cell therapy, must take into consideration
several primary factors so as to minimize microbial death
and maximize therapeutic eﬀectiveness. To assure their
eﬃcacy, artiﬁcial cells intended for oral administration
mustbedesignedtoprotecttheirlivingcargoagainstboth
acidic environment of the stomach and immunoglobu-
lin released by the intestinal immune response. For this
reason research has historically focused on the buﬀering
capability of microcapsule membranes in simulated hu-
mangastricenvironmentsandtheabilityofvariousmem-
branes to oppose immunoglobulin penetration. Several
examples of artiﬁcial cell design follow with emphasis on
research related to these core and essential characteristics.
Rao et al[22] described a method to encapsulate
freeze-dried B pseudolongum using cellulose acetate ph-
thalate (CAP) coated with beeswax, showing that en-
capsulated B pseudolongum is able to survive the simu-
lated gastric environment in larger numbers than non-
encapsulatedcells[22,24].ABraziliangrouprecentlypre-
pared probiotic microorganisms including Lactobacillus
and Biﬁdobacteria by spray drying, again using CAP as
the wall material, evaluated the resistance of these mi-
croorganisms to drying at three temperatures, and eval-
uated in vitro tolerance to pH values and simulated hu-
man bile concentrations [75]. They found that the CAP-
prepared microorganisms were better able to protect the
microorganisms fromanacidic environment andwere re-
sistant to conditions of a simulated human bile environ-
ment [75]. In another study, encapsulation of Biﬁdobac-
teria inbutter-oil-and-whey-based medium was proposed
but was shown to be ineﬀective in preventing acid injury
to bacteria in both low acid and high acid environments
[76].
Overall, calcium alginate and k-carrageenan-locust
bean gum gel beads have been the two most commonly
used polymers for immobilizing viable cells [77, 78]. Al-
ginate beads, however, have displayed the undesirable
property of limited acid resistance, and it has been re-
ported that alginate beads undergo shrinkage and de-
creased mechanical strength in acidic conditions [78, 79].
In order to overcome this challenge, coating the bacte-
ria by cross-linking with a carboxyvinyl polymer carrier
has been suggested and was shown to be eﬀective for in-
testinal delivery [80]. K-carrageenan-locust bean gum gel
beads are less sensitive to acidic conditions than alginate
beads and hence have been used for lactic fermentation.
The formation of k-carrageenan-locust bean gum beads,
however, requires a high concentration of potassium ions50 S. Prakash and M. L. Jones 2005:1 (2005)
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Figure 4. Electrostatic interactions of polymer layers in alginate-poly-L-lysine-alginate artiﬁcial cell membrane.
and for this reason two major limitations preclude their
widespread use: ﬁrstly, high concentrations of potassium
ions could potentially damage the cells of B longum dur-
ing lactic fermentation [81, 82]; and secondly, it has been
pointedoutthataspotassiumionsareimportantinmain-
taining electrolyte equilibrium, their inclusion in the diet
in large amounts would not be recommended [1, 83].
Gellan-xanthan beads, on the other hand, are not only
acid-resistant but are also stabilized by calcium ions [84],
suggesting that they could be a good candidate for immo-
bilizingbacterialcellsandprotectingthemagainstacidin-
jury [85]; however, gellan-xanthan beads do not provide
adequate immune protection.
Similarly, agarose microcapsules prepared by emulsi-
ﬁcation/internal gelatinization for oral delivery of Bacil-
lus Calmette-Guerin (BCG) cells, although stable for up
to 12 months in vitro, have not yet been shown suit-
able for oral delivery, as agarose membranes do not pro-
vide suﬃcient immunoprotection [84, 86]. Thus, agarose
microspheres with the addition of various polymer coat-
ingshavebeenproposed[87].Amongotherformulations,
gelatin and polymer-coated gelatin capsules have been
studied for oral delivery of live bacterial cells [88, 89]. Al-
though gelatin (with 20% w/v of the polymer) has shown
promising results in vitro, a radiological study among hu-
man volunteers has shown that uncoated gelatin capsules
disintegrate within 15 minutes of ingestion [90, 91].
Althoughahostofotherformulationshavebeenstud-
ied to date (including using gum arabic, milk-derived
whey proteins, soluble starch, and others [26, 89, 92, 93,
94, 95, 96, 97]) the most promising formulation is the en-
capsulation of calcium alginate beads with poly-L-lysine
(PLL)formingAPAmicrocapsules.IntheAPAmembrane
microcapsule, alginate forms the core and matrix for the
cell and PLL binds to the alginate core. Binding of PLL
to alginate is the result of numerous long-chain alkyl-
amino groups within PLL that extend fromthe polyamide
backbone in a number of directions and interact with
various alginate molecules, through electrostatic interac-
tions. The resulting cross-linkage produces a stable com-
plex membrane that reduces the porosity of the alginate
membrane and forms permanent immunoprotective bar-
riers as shown in Figure 4.
One possible drawback to this system is as some stud-
ies have suggested that APA microcapsules may provoke
an inﬂammatory response [105], and although the latter
wasobserved in celltransplantation studies, one canenvi-
sionthepossibilityofsimilaradversereactionsduringoral
therapy especially when large quantities of microcapsules
are used and further accentuated when the patient suﬀers
from internal GI bleeding. The conventional APA micro-
capsule has thus been shown to pose limitations for gen-
eral use in the oral administration of microencapsulated
bacterial cells for therapy. Some studies have shown that
this classic formulation has inadequate stability in the GI
tract for some applications [106], while other researchers
have shown that APA microcapsules have a controver-
sial permeability [107]. Furthermore, it has been reported
t h a ti ti sd i ﬃcult to obtain a membrane, optimizing all
the properties requested for a successful clinical applica-
tion, by the process of binary polyelectrolyte complexa-
tion [108].2005:1 (2005) Delivery of Live Bacteria in Artiﬁcial Cells for Therapy 51
A potential solution to these problems is the use of
multilayer membrane formation based on the electro-
static attraction of oppositely charged macromolecules
with a charge reversal at each step of the macroion ad-
sorption. This technique makes it possible to modu-
late the MWCO and retain high mechanical stability at
the same time. Speciﬁcally, Alginate/Poly-L-lysine/Pectin/
Poly-L-lysine/Alginate (APPPA), Alginate/Poly-L-lysine/
Pectin/Poly-L-lysine/Pectin (APPPP), and Alginate/Poly-
L-lysine/Chitosan/Poly-L-lysine/Alginate (APCPA) mem-
branes have been prepared and tested for their strength
and GI stability [109, 110]. It has been shown that these
multilayer membrane formulations perform well in GI
stability tests, providing for increased resistance to com-
plete dissolution in water, dilute acids, and base, as well as
in the presence of ion cheaters, while allowing for more
precise control over membrane permeability.
Productionandstorageofartiﬁcialcellsfororal
deliveryofbacterialcells
The considerations for production and storage of ar-
tiﬁcial cells for oral delivery of bacterial cells have been
outlined [111] and should include an evaluation of the
stresses to which probiotic products are exposed during
production and during passage in the GI tract. Certain
stresses, associated with microcapsule production, have
been identiﬁed that must be considered, including ex-
posure to high concentrations of fermentation by prod-
ucts, harvesting procedures, freezing, drying, exposure to
oxygen, and osmotic pressure from salts [111]. In the GI
tract designers must minimize the stresses of long expo-
sure times to stomach acid, antimicrobial compounds,
bile acids, and oxygen, and the stress of rehydration in a
highly acidic environment [111]. Siuta-Cruce and Goulet
haveshownthatmicroencapsulationisaneﬃcientbarrier
against chemical entities such as moisture, oxygen, and
acids, as well as a good protector against short exposure
to high temperatures and pressure [111].
Despite the numerous considerations, it has been
found that artiﬁcial cells for bacterial cell therapy can
be successfully stored and delivered in several diﬀerent
formulation modalities. Microencapsulated bacterial cells
can be incorporated into foodstuﬀss u c ha sf e r m e n t e d
milk products (yogurt and ice cream) as active ingredi-
ents, or can be added as a nonactive supplement to food
products in their microencapsulated form. Alternatively,
microcapsules carrying bacterial cells can be dehydrated
and incorporated into capsules or into pill form with a
shelf-life of up to two years [112]. Institute Rosell part-
nered with Balchem have reported results in which en-
capsulatedbacteria,incorporatedintocompressedtablets,
have an unprecedented 100% delivery rate compared
to the industry standard of 50%–75% bacterial survival
in compressed tablets [111]. Also, microcapsules can be
stored for months at low temperature in minimal solu-
tion and can be administered in drink format (Figure 5).
Table 2 is a comprehensive list of the potential therapies
(a) (b) (c)
Figure 5. Artiﬁcial cells for bacterial cell therapy can be stored
and delivered in several ways. (a) Microencapsulated bacterial
cells can be incorporated into foodstuﬀs such as fermented milk
products (yogurt and ice cream). (b) Microcapsules can be de-
hydrated and incorporated into capsules or into pill form with
a shelf-life of up to two years. (c) Microcapsules can be stored
for months at low temperature in minimal solution and can be
administered in drink format.
based on the oral delivery of artiﬁcial cell microencapsu-
lated bacterial cells for therapy [63, 75, 88, 96, 97, 98, 99,
100, 101, 102, 103, 104].
FUTURE DIRECTION
Recombinant technology will continue to generate
valuable nonpathogenic genetically engineered bacterial
cells and other genetically engineered cells that have po-
tentially therapeutic functions or that produce therapeu-
tic products useful in the treatment of disease. Future re-
search must focus on overcoming the inherent obstacles
in delivering these engineered products to therapeutically
relevant and favorable sites. Thus, improvements must
be centered on the design of microcapsule membranes,
methodsforimprovedcellharvestandmicrocapsulemass
production, and methods of low-cost and eﬀective stor-
age. Currently, however, microencapsulation appears to
be the best available technology to preserve the potency of
probiotic products to be delivered into the GI tract; thus,
future investigation may prove to allow for the eﬃcient
and eﬀective use of bacteria in therapeutics or advanced
food systems and allow manufactures to place assurances
on the viability and quantity of bacteria in such advanced
therapeutics and food products.
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Table 2. Potential therapies based on the oral delivery of microencapsulated bacterial cells.
Disease/therapy Culture Mode of Action References
Kidney dialysis Ec o l iDH5
Inserted Klebsiella aerogenes urease gene causes overexpression of
the urease enzyme and the subsequent lowering of elevated blood
levels of urea. Blood levels of other metabolites, such as ammonia,
experience similar decreases showing that the DH5 cells normalize
elevated levels of several elevated metabolites during renal failure.
[63, 98]
US
Patent
6 217 859
Kidney stones O formigenes
Oxalate-degrading enzymes produced by Oxalobacter formigenes
b r e a k sd o w nu n w a n t e do x a l a t e ,am a j o rr i s kf a c t o rf o rr e n a ls t o n e
formation and growth in patients with idiopathic calcium-oxalate
urolithiasis, and can be used to prevent subsequent evolution of
kidney stones.
[99, 100]
US
Patent
6 242 230
Elevated blood
levels of
cholesterol
LP80 (pCBH1)
and Lr e u t e r i
Overproduced BSH enzyme deconjugates intraluminal bile acids
making them less likely to be reabsorbed into the ECH, causing de
novo synthesis of bile acids in the liver from blood serum cholesterol.
Lr e u t e r ican be microencapsulated in combination with LP80
(pCBH1), as it has been shown to precipitate and bind bile acids,
making them less bioavailable which may be important to their
carcinogenic potential.
[101]
US
Provisional
Patent
1770-
325USPR
FC/jm
Preventative
therapy for
colon cancer
LP80 (pCBH1)
and Lr e u t e r i
The BSH enzyme is overproduced by LP80 (pCBH1) cells and
hydrolyzes available conjugated bile acids in the intestinal lumen. L
reuteri, shown to precipitate and bind bile acids, then binds the
deconjugated bile acids making them incapable of leaving the
microcapsule and thus less bioavailable for exfoliation of the GI and
any potential carcinogenic damage.
[101]
US
Provisional
Patent
1770-
325USPR
FC/jm
Disease of the
bowel (elevated
intraluminal
levels of bile
acids)
LP80 (pCBH1)
and Lr e u t e r i
LP80 (pCBH1) and Lr e u t e r ideconjugate, precipitate, and then bind
conjugated bile acids within microcapsules, mitigating the problems
associated with excessive electrolyte and water secretion associated
clinically with diarrhea and dehydration.
[101]
US
Provisional
Patent
1770-
325USPR
FC/jm
Probiotics
Lactobacillus
Biﬁdobacterium
Live microorganisms used as dietary supplements with the aim of
beneﬁting the health of the consumer by positively inﬂuencing their
intestinal microbial balance. Microencapsulated probiotic bacteria
should help alleviate diarrhea, lower cholesterol, modulate immunity,
and prevent colon cancer.
[75, 88,
96, 97,
102]
Elevated blood
levels of
amino acids
Chang et al—“cell
cultures which can
convert, metabolize,
or remove speciﬁc
amino acids”
Lowers elevated blood levels of various amino acids through their
metabolism, for example, phenylalanine in phenylketonuria.
[98, 103]
US
Patents
6 217 859,
5 147 641
Elevated blood
levels of
nitrogen and
hydrogen gas
H2 metabolizing
(Ms m i t h i i )
N2 ﬁxing
(Enterobacteriaceae)
Live microorganisms delivered orally to a diver’s large intestine
during hyperbaric exposure to a gas mixture containing H2 or N2
metabolizes the H2 or N2 gas to other compounds such as methane or
water for hydrogen and ammonia for nitrogen to prevent
decompression sickness or reduce decompression time.
[104]
US Patent
5 922 3172005:1 (2005) Delivery of Live Bacteria in Artiﬁcial Cells for Therapy 53
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